Clinical review report Edoxaban (Lixiana)
Taken orally, Edoxaban is a highly selective, direct, and reversible inhibitor of factor Xa. It has a Health Canada indication for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)) and the prevention of recurrent DVT and PE. The manufacturer has r...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820283106719 |
